Relevance of Isoniazid Dosage in Adults Treated for Tuberculosis

Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Sep 19, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of isoniazid, a key medication used to treat tuberculosis (TB), to see how different doses can impact patients. Tuberculosis is a serious disease that can be deadly, and isoniazid is one of the main drugs used to fight it. The researchers want to find out if the standard dose of isoniazid is right for everyone, as some people may process the drug differently. By looking at how patients respond to the medication, the trial aims to ensure that everyone receives the right amount to avoid side effects like liver damage or nerve issues.

To participate in this trial, you need to be an adult who has been diagnosed with tuberculosis. Unfortunately, if you are pregnant or do not want to participate, you won't be eligible. If you join, you can expect to have your blood tested to see how your body is handling the medication. This could help doctors understand more about the best ways to use isoniazid and improve treatment for future patients with TB. The trial is currently recruiting participants, so it’s a chance to contribute to important research while receiving care for your condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • to be an adult,
• • to have a diagnosis of tuberculosis
• Exclusion Criteria:
• • pregnancy,
• • disagreement to participate